Search Results
#
Update: Motor Outcomes to Validate Evaluations in FSHD
Aug 4, 2024, 11:03 AM
MOVE FSHD study update.
#
Update: Motor Outcomes to Validate Evaluations in FSHD
Feb 17, 2024, 5:59 PM
An update on the MOVE FSHD study.
#
Update: Motor Outcomes to Validate Evaluations in FSHD
Oct 10, 2023, 5:23 PM
Latest update from the MOVE grant.
#
Update: Motor Outcomes to Validate Evaluations in FSHD
Feb 5, 2023, 12:03 PM
This large study will be a big achievement in the FSHD community, a reality that has been made possible by the support from Friends of FSH Research.
#
Update: Motor Outcomes to Validate Evaluations in FSHD
Aug 4, 2022, 12:37 PM
Update on MOVE FSHD study.
#
2022 FSHD Research Update Meeting
Feb 7, 2022, 1:05 PM
Annual research update meeting information.
#
Progress Update: Motor Outcomes to Validate Evaluations in FSHD
Jan 25, 2022, 2:26 PM
Dr. Statland provides an 18 month update on the current state of CTRN.
#
Progress Update: Motor Outcomes to Validate Evaluations in FSHD
Jul 15, 2021, 3:57 PM
Dr. Statland provides a second update on the MOVE FSHD Study.
#
Clinical trial network aims to speeding up development of effective treatments for rare type of muscular dystrophy
Jun 18, 2021, 3:34 PM
Article published by University of Kansas Medical Center provides insight into work by Dr. Jeffrey Statland, partially supported through multiple grants from Friends of FSH Research.
#
Progress Update: CTRN International Sites
May 7, 2021, 4:37 PM
Dr. Tawil provides a final progress update.
#
Progress Update: Motor Outcomes to Validate Evaluations in FSHD
Mar 6, 2021, 8:56 AM
Dr. Statland provides an update to the MOVE FSHD study.
#
Progress Update: CTRN International Sites
Sep 14, 2020, 4:48 PM
Dr. Rabi Tawil provides an update on the expansion of the ReSolve Study to include two European Sites.
#
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
Jul 23, 2020, 4:22 PM
A grant to Drs. Statland and Tawil in support of a multi-year study.
#
Dyne Therapeutics Accelerates Programs in FSHD
May 19, 2020, 2:22 PM
Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization University of Mons
#
CTRN ReSolve FSHD Update
Nov 6, 2019, 3:25 PM
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (ReSolve FSHD).
#
Progress Update: CTRN International Sites
Aug 1, 2019, 12:08 PM
Dr. Tawil provides a brief update on the two CTRN European sites funded.
#
CTRN ReSolve FSHD Update
Jul 19, 2019, 2:28 PM
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (ReSolve FSHD).
#
Progress Update: CTRN International Sites
Nov 5, 2018, 5:19 PM
Dr. Tawil provides a brief update on the two CTRN European sites funded.
#
Genea Biocells Announces FDA Orphan Drug Designation for GBC0905 for the Treatment of FSHD
Jun 1, 2018, 7:48 AM
Genea Biocells announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its therapeutic candidate, GBC0905,
#
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
May 25, 2018, 11:43 AM
As multiple drug companies pursue treatments for FSHD, there is an urgent need to define the clinical trial strategies which will hasten drug development, including creating disease-relevant outcome measures and optimizing inclusion criteria. This proposal will develop two new outcome measures and optimize eligibility criteria by testing 160 patients in 7 sites over a period of 18 months.
#
Acceleron to Webcast Overview of ACE-083 Phase 2 Trial
Oct 27, 2016, 10:00 AM
Webcast to be held Oct 28, 2016 at 10:00 a.m. EDT with Dr. Statland. Archive available on website.